Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 675 of 866 entries
View as:

A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2)

Phase: N/A Priority: Normal
NCT ID: NCT02738138 Org: User:
Start: 05/17/16 End: 06/07/17 Due: 06/07/18

Patient- and Caregiver-reported Symptoms and Outcomes With Levodopa/Carbidopa Intestinal Gel for the Treatment of Advanced Parkinson's Disease

Phase: N/A Priority: Normal
NCT ID: NCT02289729 Org: User:
Start: 10/31/14 End: 11/30/16 Due: 11/30/17

Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, With Severe Kidney Impairment or End Stage Kidney Disease

Phase: N/A Priority: Normal
NCT ID: NCT02487199 Org: User:
Start: 09/30/15 End: 12/05/16 Due: 12/05/17

A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs

Phase: N/A Priority: Normal
NCT ID: NCT02720523 Org: User:
Start: 03/22/16 End: 06/07/22 Due: 06/07/23

Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study

Phase: N/A Priority: Normal
NCT ID: NCT02798315 Org: User:
Start: 05/25/16 End: 06/12/17 Due: 06/12/18

A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT05601882 Org: User:
Start: 11/28/22 End: 08/08/24 Due: 08/08/25

Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C

Phase: N/A Priority: Normal
NCT ID: NCT02817594 Org: User:
Start: 01/20/16 End: 03/07/18 Due: 03/07/19

Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02470585 Org: User:
Start: 07/14/15 End: 10/05/23 Due: 10/05/24

Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT04492020 Org: User:
Start: 08/21/20 End: 04/19/22 Due: 04/19/23

A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers

Phase: N/A Priority: Normal
NCT ID: NCT04272203 Org: User:
Start: 05/05/20 End: 06/27/22 Due: 06/27/23

HUMIRA® Long-term Treatment in Patients With Non-infectious Intermediate-, Posterior-, or Pan-uveitis

Phase: N/A Priority: Normal
NCT ID: NCT02916017 Org: User:
Start: 11/15/16 End: 10/14/20 Due: 10/14/21

Expanded Access to Epcoritamab

Phase: N/A Priority: Normal
NCT ID: NCT05692050 Org: User:
Start: - End: - Due: -

Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium

Phase: N/A Priority: Normal
NCT ID: NCT02581163 Org: User:
Start: 10/07/15 End: 02/12/18 Due: 02/12/19

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)

Phase: N/A Priority: Normal
NCT ID: NCT03104400 Org: User:
Start: 04/27/17 End: 09/09/24 Due: 09/09/25

Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement

Phase: N/A Priority: Normal
NCT ID: NCT04713592 Org: User:
Start: 02/26/21 End: 04/20/23 Due: 04/20/24

A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian Participants

Phase: N/A Priority: Normal
NCT ID: NCT06673238 Org: User:
Start: 10/29/24 End: 07/04/25 Due: 07/04/26

Expanded Access to Risankizumab

Phase: N/A Priority: Normal
NCT ID: NCT03914261 Org: User:
Start: - End: - Due: -

A Study of Oral Upadacitinib Tablets to Assess the Change in Disease Symptoms in Adult Canadian Participants With Moderate to Severe Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT04574492 Org: User:
Start: 10/07/20 End: 07/30/24 Due: 07/30/25

An Observational Study of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic Hepatitis C Genotypes 1 to 6 Patients According to the Standard for Re-examination of New Drugs

Phase: N/A Priority: Normal
NCT ID: NCT03740230 Org: User:
Start: 09/26/18 End: 07/21/23 Due: 07/21/24

A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before

Phase: N/A Priority: Normal
NCT ID: NCT01854697 Org: User:
Start: 03/31/13 End: 07/31/15 Due: 07/31/16

An Efficacy and Safety Study of Injectable Ravagalimab to Assess Change in EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) in Adult Participants With Moderately to Severely Active Primary Sjogren's Syndrome (pSS)

Phase: N/A Priority: Normal
NCT ID: NCT05217472 Org: User:
Start: 03/06/20 End: 05/15/22 Due: 05/15/23

A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused ABBV-383 of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan

Phase: N/A Priority: Normal
NCT ID: NCT05286229 Org: User:
Start: 03/24/22 End: 03/30/25 Due: 03/30/26

An Observational Study to Assess Change in Disease Activity When Ubrogepant Tablets Are Combined With Atogepant Tablets to Treat Migraine in Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT05653986 Org: User:
Start: 12/18/22 End: 08/05/24 Due: 08/05/25

A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS)

Phase: N/A Priority: Normal
NCT ID: NCT02966782 Org: User:
Start: 03/07/17 End: 04/05/23 Due: 04/05/24

An Observational Study of Subcutaneous Infusion of ABBV-951 to Assess Change in Disease Activity and Adverse Events In Adult Japanese Participants With Advanced Parkinson's Disease

Phase: N/A Priority: Normal
NCT ID: NCT05916157 Org: User:
Start: 11/30/23 End: 07/31/26 Due: 07/31/27